about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmiasAdenosine receptors and asthma in humansRapamycin and mTOR kinase inhibitorsGlobal expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulationQingfei Xiaoyan Wan alleviates asthma through multi-target network regulationThe effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program.The Saudi Initiative for Asthma.Theophylline.Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine.Drug screening in a zebrafish model of Duchenne muscular dystrophy.The effect of pulse methylprednisolone plus theophylline treatment on clinical, pulmonary and inflammatory markers in relapses of multiple sclerosisThe Effect of Acebrophylline vs Sustained Release Theophylline in Patients of COPD- A Comparative StudyLung injury after simulated cardiopulmonary bypass in an isolated perfused rat lung preparation: Role of mitogen-activated protein kinase/Akt signaling and the effects of theophylline.Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year.Regulated Expression Systems for Mycobacteria and Their ApplicationsABC of chronic obstructive pulmonary disease. Pharmacological management--oral treatment.CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activitiesDemographic and Clinical Characteristics of Theophylline Exposures between 1993 and 2011.Potential therapeutic effect of Allium cepa L. and quercetin in a murine model of Blomia tropicalis induced asthma.On the progressive nature of emphysema: roles of proteases, inflammation, and mechanical forces.Biochemical basis of asthma therapy.Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPDHow corticosteroids control inflammation: Quintiles Prize Lecture 2005Drugs for asthmaAsthma, airway biology, and nasal disorders in AJRCCM 2003.Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2003.[Allergic asthma in central Tunisia].Aptamers for pharmaceuticals and their application in environmental analytics.Haemophilus influenzae induces steroid-resistant inflammatory responses in COPD.Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.Maintenance pharmacotherapy of chronic obstructive pulmonary disease: an evidence-based approach.Gene therapy for chronic obstructive pulmonary disease: twilight or triumph?3-Carb-oxy-phenyl-boronic acid-theophylline (1/1)Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment.Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD.Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease.
P2860
Q24202545-F8ECE2FC-F9E5-472E-B146-E2CCF0D9554AQ24234493-C60BE5D8-0B4E-479C-8928-532D90A798FBQ24243560-3D90B3B1-3E74-461B-9F9E-AA84F5487A3DQ24337832-596706EE-954F-460F-B7D0-21191D2F49CBQ24644125-E8FAB008-5E71-4709-8B0E-830CF00A2EDDQ24644623-D52214F2-B98E-439C-B8B2-8C55B1647FCBQ24815017-0EDDF028-5880-4EA8-AEA0-2B972B333AB0Q30544207-8F49F654-CA4F-4A4E-A2A4-01938BB0C6F4Q30820703-2A7DD83A-ECBE-4EEC-B8F9-4AE8CA322E97Q33568644-2FCF28A8-3B2B-4458-B4CF-526F391EB902Q33664235-9CD91827-4B6F-4109-8F14-EBB49D153312Q33703117-2A8CCFBA-B66F-40CA-8677-8748FFB8BFF4Q33845739-A97CB38F-FFB8-4E21-BF63-D9995CFE7CF0Q33974404-ED874EFD-6F7A-4351-B97E-09A2154D9D8BQ34479822-B75F0E9E-7AFB-460C-BB5D-D21A560288D2Q34483321-096C7E22-5086-423E-87F1-A6799B814460Q34558280-E002372A-F8AD-4CA9-84B5-D34BAEBC5630Q34626585-F410F367-DF1B-4FFC-9EEF-698C746699FEQ34693261-DA81ADB7-7BC1-4172-8748-B2C42751AC55Q35048762-D9CBABE8-05B6-4E26-BC4E-746BF8D21796Q35053372-0570568D-5F94-41BE-B778-DBB71778454EQ35132100-785A9642-C808-4DA8-87BA-2232DB54E2D4Q35207006-E47254F8-C231-4131-872C-9B5B354088ECQ35312155-508DE1F5-EB89-40AA-B0CC-9200D8DA0E82Q35492192-1CD8F141-0FD3-49A2-B793-9477F2B023F4Q35545886-9DCC1C62-7D6D-4A1B-BF8D-A18A769756ACQ35566594-80697446-637B-4C4C-9375-2D56E3E4F077Q35626613-D0D32B61-C2D4-483D-BF2B-F66ED39B7A1AQ35626624-1B1132E7-0B8B-46BB-B023-A3A3AB556255Q35714691-83C10EB3-659D-4F4C-AD7E-E031E6821C81Q35761658-8F35DD3C-F265-470B-8F28-2C457EAFEFA9Q35862720-98779991-B7E5-4099-A9BA-79129F2F9537Q35876360-8ED8304D-CC49-4115-9CD4-EE5A18C85F49Q36040655-81163580-03FF-470E-AC57-3BD6B2FAEF3FQ36099456-170F77A8-40BC-4192-8928-3C53590E40F0Q36148475-765A18B1-91F6-4DA1-87F4-E5D0F6A9F9FAQ36165890-4A0F9812-090C-4320-AD36-FE04048A67CDQ36318525-1FD18917-EA8B-4FC0-9551-FB5259491275Q36365175-B3355BC3-BDC5-44D5-BA28-9EEEC4ED67C3Q36379352-F2F59349-461A-453A-94FF-4ADBC76C6BE2
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Theophylline: new perspectives for an old drug.
@ast
Theophylline: new perspectives for an old drug.
@en
type
label
Theophylline: new perspectives for an old drug.
@ast
Theophylline: new perspectives for an old drug.
@en
prefLabel
Theophylline: new perspectives for an old drug.
@ast
Theophylline: new perspectives for an old drug.
@en
P2860
P1476
Theophylline: new perspectives for an old drug.
@en
P2093
Peter J Barnes
P2860
P304
P356
10.1164/RCCM.200210-1142PP
P407
P577
2003-03-01T00:00:00Z